NAD+ vs FOXO4-DRI: Mechanism, Evidence, FDA Status, Dosing and Cost

NAD+ is nicotinamide adenine dinucleotide. It is not a peptide. It is a coenzyme, two nucleotides joined together, one carrying nicotinamide (a form of vitamin B3) and the other adenine, and every living cell makes it and uses it continuously. The body builds most of it by recycling nicotinamide through nicotinamide mononucleotide (NMN); nicotinamide riboside (NR) is another way into that pathway. NMN and NR are the "precursors" sold as supplements, and most of the human trial literature is about them rather than NAD+ itself. The full reference is at what is NAD+ injection.

• Carrying electrons. NAD+ picks up electrons from broken-down glucose and fat, becomes NADH, and hands them to the mitochondria to make ATP. This is textbook biochemistry.
• Fuel for sirtuins. Sirtuins (SIRT1 to SIRT7) consume NAD+ each time they act. A 2015 review in Science by Verdin set out the case, from cell and animal work, that declining NAD+ limits sirtuin activity with age.
• Fuel for PARP enzymes and DNA repair. PARP enzymes respond to DNA damage and spend NAD+ in the process. A 2014 review in Cell Cycle by Fang and Bohr described how PARPs and sirtuins draw on the same limited pool.
• Levels fall with age. A 2012 study in PLOS ONE measured NAD+ in human skin across age groups and reported lower levels in older tissue. That is human data, and it is observational: it shows the decline, not that reversing it changes anything.

Oral precursors reliably raise blood NAD+ in randomized trials, with small and inconsistent effects on things like insulin sensitivity and walking distance. The only published study of NAD+ given directly to people, a 2019 pilot in Frontiers in Aging Neuroscience, infused it intravenously over six hours and found plasma NAD+ did not rise at all for the first two hours; the molecule was cleared as fast as it arrived. There are no randomized controlled trials of subcutaneous NAD+ injection in humans. More is in NAD+ benefits.

FOXO4-DRI is not a fragment of anything the body makes. It was designed in the laboratory of Peter de Keizer at Erasmus University Medical Center in Rotterdam and described in a 2017 paper in Cell. The starting point was FOXO4, a transcription factor that senescent cells use to stay alive: it holds onto p53, the protein that normally decides whether a damaged cell dies. The peptide copies a stretch of FOXO4 and acts as a decoy.

A senescent cell is one that has stopped dividing permanently but has not died. It sits in tissue and secretes inflammatory signals, a pattern called the senescence-associated secretory phenotype. The senolytic hypothesis is that removing these cells improves the tissue around them. "DRI" stands for D-retro-inverso: the sequence is built backwards from mirror-image D-amino acids so enzymes do not break it down, with a cell-penetrating tail attached. The full reference is at what is FOXO4-DRI.

• Blocking the FOXO4 and p53 interaction. The 2017 Cell paper reports that FOXO4-DRI competes with FOXO4 for p53 in senescent cells. A 2025 structural paper in Nature Communications reported that it binds the same region of p53 that natural FOXO4 uses.
• Letting the cell's own death programme run. Once freed, p53 is described leaving the nucleus and triggering apoptosis. Cell work in 2025 and 2026 filled in the downstream steps.
• Selectivity. The Cell paper reports apoptosis in senescent cells but not in dividing cells in culture. A 2021 study on human cartilage cells grown in a dish reported the same selective removal.

All of the mechanism work is in mice and in cells.

None. There are no randomized human trials of FOXO4-DRI, no non-randomized trials, no dose-finding study and no human safety or pharmacokinetic study. The headline findings, restored fitness, fur density and kidney function in aged and fast-aging mice, came from a short course of injections into the abdominal cavity, not weeks of subcutaneous dosing. Later studies in mice and in human cells in a dish looked at testis cells, lung fibrosis, keloid scar tissue and blood vessels.

NAD+ is the more conventional starting point when the interest is cellular energy, fatigue that has been worked up, or a general longevity conversation with some human research behind it. It is a molecule the body already makes, it has a human tolerability record from the precursor trials, and the FOXO4-DRI page itself notes that NAD+ is the more defensible choice for someone who wants one anti-aging intervention with human data. The 500 mg vial gives a lower dose per injection with the same draw.

FOXO4-DRI suits a narrower group: people who understand they are choosing an experimental compound with no human data, specifically to try the senolytic hypothesis. It is the only senolytic in Pepti's catalogue. Senescent cell clearance, if it happens, is not something a person would feel, so most people notice nothing during a course, and there is no marker a patient can watch.

They act on different systems and nothing in the literature describes an interaction, but no study has tested the combination, so it means two sets of unknowns at once. Most people start with one. If both are being considered, tell your physician on the intake, and your directions for each will be printed on its vial.